Clinical Trial Update: Bortezomib to Treat Significant Complication of HSCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on using bortezomib to treat significant complications after allogeneic stem cell transplantation; results have been posted. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Cytopenia

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Allogeneic Stem Cell Transplantation, Refractory Autoimmune Cytopenia(s) | Phase 2 | Status: COMPLETED | Results posted: 2016-10-24